Iomeron (Iomeprol)

Iomeprol contains iodine atoms with high atomic number, which absorb X‑ray photons more effectively than surrounding tissues. This increased attenuation creates a stark difference in radiodensity, allowing clinicians to see vascular and soft‑tissue structures with greater clarity on radiographic, CT, and myelographic images.

The dose of Iomeron is individualized by the prescribing physician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. Only a qualified healthcare professional should determine the appropriate volume and concentration.

The safety of Iomeron in pregnancy and lactation has not been definitively established. It should be used only if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iomeron (Iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality while reducing the incidence of discomfort and adverse renal effects, making it a preferred choice for many diagnostic imaging procedures.

Iomeron should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Iomeron is administered by a qualified healthcare professional as an injection into a vein, artery, or the intrathecal space, depending on the imaging study. The injection is performed under sterile conditions, and the volume is tailored to the diagnostic requirement.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury (contrast‑induced nephropathy), and rare neurologic events like seizures. Immediate medical attention is required if any signs of these reactions appear during or after administration.

Iomeron is contraindicated in patients with a known hypersensitivity to iodine or any component of the formulation, those with severe uncontrolled asthma, and individuals with compromised renal function where alternative imaging strategies are available. The prescribing clinician must evaluate each patient’s medical history before use.